114 related articles for article (PubMed ID: 28968593)
1. GSK3α/β: A Novel Therapeutic Target for Neuroendocrine Tumors.
Aristizabal Prada ET; Weis C; Orth M; Lauseker M; Spöttl G; Maurer J; Grabowski P; Grossman A; Auernhammer CJ; Nölting S
Neuroendocrinology; 2018; 106(4):335-351. PubMed ID: 28968593
[TBL] [Abstract][Full Text] [Related]
2. GSK3β suppression inhibits MCL1 protein synthesis in human acute myeloid leukemia cells.
Lee YC; Shi YJ; Wang LJ; Chiou JT; Huang CH; Chang LS
J Cell Physiol; 2021 Jan; 236(1):570-586. PubMed ID: 32572959
[TBL] [Abstract][Full Text] [Related]
3. The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro.
Aristizabal Prada ET; Nölting S; Spoettl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):58-73. PubMed ID: 28226315
[TBL] [Abstract][Full Text] [Related]
4. Perifosine-mediated Akt inhibition in neuroendocrine tumor cells: role of specific Akt isoforms.
Zitzmann K; Vlotides G; Brand S; Lahm H; Spöttl G; Göke B; Auernhammer CJ
Endocr Relat Cancer; 2012 Jun; 19(3):423-34. PubMed ID: 22499437
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase-3 inhibitor AR-A014418 suppresses pancreatic cancer cell growth via inhibition of GSK-3-mediated Notch1 expression.
Kunnimalaiyaan S; Gamblin TC; Kunnimalaiyaan M
HPB (Oxford); 2015 Sep; 17(9):770-6. PubMed ID: 26147011
[TBL] [Abstract][Full Text] [Related]
6. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.
Madhunapantula SV; Sharma A; Gowda R; Robertson GP
Pigment Cell Melanoma Res; 2013 Nov; 26(6):886-99. PubMed ID: 24034838
[TBL] [Abstract][Full Text] [Related]
7. Aspirin inhibits cell viability and mTOR downstream signaling in gastroenteropancreatic and bronchopulmonary neuroendocrine tumor cells.
Spampatti M; Vlotides G; Spöttl G; Maurer J; Göke B; Auernhammer CJ
World J Gastroenterol; 2014 Aug; 20(29):10038-49. PubMed ID: 25110431
[TBL] [Abstract][Full Text] [Related]
8. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth.
Carter YM; Kunnimalaiyaan S; Chen H; Gamblin TC; Kunnimalaiyaan M
Cancer Biol Ther; 2014 May; 15(5):510-5. PubMed ID: 24521712
[TBL] [Abstract][Full Text] [Related]
9. The HDM2 (MDM2) Inhibitor NVP-CGM097 Inhibits Tumor Cell Proliferation and Shows Additive Effects with 5-Fluorouracil on the p53-p21-Rb-E2F1 Cascade in the p53wild type Neuroendocrine Tumor Cell Line GOT1.
Reuther C; Heinzle V; Nölting S; Herterich S; Hahner S; Halilovic E; Jeay S; Wuerthner JU; Aristizabal Prada ET; Spöttl G; Maurer J; Auernhammer CJ
Neuroendocrinology; 2018; 106(1):1-19. PubMed ID: 27871087
[TBL] [Abstract][Full Text] [Related]
10. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
11. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways.
Nölting S; Maurer J; Spöttl G; Aristizabal Prada ET; Reuther C; Young K; Korbonits M; Göke B; Grossman A; Auernhammer CJ
PLoS One; 2015; 10(12):e0143830. PubMed ID: 26636335
[TBL] [Abstract][Full Text] [Related]
12. Type 2 Diabetes in Neuroendocrine Tumors: Are Biguanides and Statins Part of the Solution?
Herrera-Martínez AD; Pedraza-Arevalo S; L-López F; Gahete MD; Gálvez-Moreno MA; Castaño JP; Luque RM
J Clin Endocrinol Metab; 2019 Jan; 104(1):57-73. PubMed ID: 30265346
[TBL] [Abstract][Full Text] [Related]
13. Anticancer effects of metformin on neuroendocrine tumor cells in vitro.
Vlotides G; Tanyeri A; Spampatti M; Zitzmann K; Chourdakis M; Spttl C; Maurer J; Nölting S; Göke B; Auernhammer CJ
Hormones (Athens); 2014; 13(4):498-508. PubMed ID: 25402373
[TBL] [Abstract][Full Text] [Related]
14. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418.
Bhat R; Xue Y; Berg S; Hellberg S; Ormö M; Nilsson Y; Radesäter AC; Jerning E; Markgren PO; Borgegård T; Nylöf M; Giménez-Cassina A; Hernández F; Lucas JJ; Díaz-Nido J; Avila J
J Biol Chem; 2003 Nov; 278(46):45937-45. PubMed ID: 12928438
[TBL] [Abstract][Full Text] [Related]
15. Glycogen synthase kinase 3β as a potential therapeutic target in synovial sarcoma and fibrosarcoma.
Abe K; Yamamoto N; Domoto T; Bolidong D; Hayashi K; Takeuchi A; Miwa S; Igarashi K; Inatani H; Aoki Y; Higuchi T; Taniguchi Y; Yonezawa H; Araki Y; Aiba H; Minamoto T; Tsuchiya H
Cancer Sci; 2020 Feb; 111(2):429-440. PubMed ID: 31808966
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic effect of glycogen synthase kinase 3beta inhibition against human glioblastoma.
Miyashita K; Kawakami K; Nakada M; Mai W; Shakoori A; Fujisawa H; Hayashi Y; Hamada J; Minamoto T
Clin Cancer Res; 2009 Feb; 15(3):887-97. PubMed ID: 19188159
[TBL] [Abstract][Full Text] [Related]
17. Combination of 5-Fluorouracil with Epigenetic Modifiers Induces Radiosensitization, Somatostatin Receptor 2 Expression, and Radioligand Binding in Neuroendocrine Tumor Cells In Vitro.
Jin XF; Auernhammer CJ; Ilhan H; Lindner S; Nölting S; Maurer J; Spöttl G; Orth M
J Nucl Med; 2019 Sep; 60(9):1240-1246. PubMed ID: 30796167
[TBL] [Abstract][Full Text] [Related]
18. GSK3 inhibitor AR-A014418 promotes osteogenic differentiation of human adipose-derived stem cells via ERK and mTORC2/Akt signaling pathway.
Zhang M; Zhang P; Liu Y; Zhou Y
Biochem Biophys Res Commun; 2017 Aug; 490(2):182-188. PubMed ID: 28602697
[TBL] [Abstract][Full Text] [Related]
19. The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice.
Martins DF; Rosa AO; Gadotti VM; Mazzardo-Martins L; Nascimento FP; Egea J; López MG; Santos AR
J Pain; 2011 Mar; 12(3):315-22. PubMed ID: 20705523
[TBL] [Abstract][Full Text] [Related]
20. Glycogen synthase kinase 3-specific inhibitor AR-A014418 decreases neuropathic pain in mice: evidence for the mechanisms of action.
Mazzardo-Martins L; Martins DF; Stramosk J; Cidral-Filho FJ; Santos AR
Neuroscience; 2012 Dec; 226():411-20. PubMed ID: 23000630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
